---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342336"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2026-08-10T20:05:18+00:00"
generated_at: "2026-08-10T20:08:52.840795+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enanta Q3 FY26 net loss $19.5M; cash $211.5M; RSV and immunology programs on track

## Summary
- Revenue $14.4M from MAVYRET royalties, down from $18.3M YoY; net loss $19.5M ($0.67/sh) vs $18.3M ($0.85/sh).
- Cash and marketable securities $211.5M; runway into fiscal 2029; OMERS gets 54.5% of royalties through 2032.
- Dosing started in LOTUS Phase 2b pediatric RSV trial of zelicapavir; topline expected 2027; RESOLVE to initiate in 4Q 2026.
- EDP-978 Phase 1 topline data expected 4Q 2026; EPS-3903 IND filing targeted 2H 2026; MRGPRX2 candidate selection 2H 2026.
- Federal Circuit affirmed invalidity of Pfizer patent; Enanta filed rehearing petition; UPC hearing set for Sept 29, 2026.

## SEC filing metadata
- accession: 0001193125-26-342336
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2026-08-10T20:05:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/0001193125-26-342336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342336
- JSON: https://secwatch.observer/filing/0001193125-26-342336.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.